{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:37:30Z","timestamp":1792816650949,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"a Health, Labour and Welfare Sciences research grant","award":["26FC0201"],"award-info":[{"award-number":["26FC0201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01066-z","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:35:51Z","timestamp":1792769751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and Emerging Therapies for Generalized Myasthenia Gravis: Toward Precision Medicine"],"prefix":"10.1007","author":[{"given":"Masaaki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-3183","authenticated-orcid":false,"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"26","key":"1066_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u201381. https:\/\/doi.org\/10.1056\/NEJMra1602678.","journal-title":"N Engl J Med"},{"issue":"3","key":"1066_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","volume":"296","author":"KV Toyka","year":"1977","unstructured":"Toyka KV, Drachman DB, Griffin DE, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977;296(3):125\u201331. https:\/\/doi.org\/10.1056\/NEJM197701202960301.","journal-title":"N Engl J Med"},{"issue":"3","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365\u20138. https:\/\/doi.org\/10.1038\/85520.","journal-title":"Nat Med"},{"issue":"2","key":"1066_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein\u00a04 in myasthenia gravis. Ann Neurol. 2011;69(2):418\u201322. https:\/\/doi.org\/10.1002\/ana.22312.","journal-title":"Ann Neurol"},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","volume":"200","author":"MR Tannemaat","year":"2024","unstructured":"Tannemaat MR, Huijbers MG, Verschuuren JJGM. Myasthenia gravis\u2014pathophysiology, diagnosis, and treatment. Handb Clin Neurol. 2024;200:283\u2013305. https:\/\/doi.org\/10.1016\/B978-0-12-823912-4.00026-8.","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1066_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","volume":"272","author":"SNM Binks","year":"2025","unstructured":"Binks SNM, Morse IM, Ashraghi M, Vincent A, Waters P, Leite MI. Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol. 2025;272(3):226. https:\/\/doi.org\/10.1007\/s00415-025-12922-7.","journal-title":"J Neurol"},{"issue":"3","key":"1066_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"issue":"4","key":"1066_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","volume":"267","author":"J Rath","year":"2020","unstructured":"Rath J, Brunner I, Tomschik M, et al. Frequency and clinical features of treatment-refractory myasthenia gravis. J Neurol. 2020;267(4):1004\u201311. https:\/\/doi.org\/10.1007\/s00415-019-09667-5.","journal-title":"J Neurol"},{"issue":"12","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase\u00a03, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1066_CR10","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066.","journal-title":"NEJM Evid"},{"issue":"5","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase\u00a03 study. Lancet Neurol. 2023;22(5):395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1066_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1066_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase\u00a03 study. Lancet Neurol. 2023;22(5):383\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7.","journal-title":"Lancet Neurol"},{"key":"1066_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123047","volume":"461","author":"R Ricciardi","year":"2024","unstructured":"Ricciardi R, Latini E, Guida M, et al. Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: results of a study on 202 patients. J Neurol Sci. 2024;461:123047. https:\/\/doi.org\/10.1016\/j.jns.2024.123047.","journal-title":"J Neurol Sci"},{"issue":"8","key":"1066_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.clinph.2021.04.019","volume":"132","author":"A Modoni","year":"2021","unstructured":"Modoni A, Mastrorosa A, Spagni G, Evoli A. Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: a neurophysiological study. Clin Neurophysiol. 2021;132(8):1845\u20139. https:\/\/doi.org\/10.1016\/j.clinph.2021.04.019.","journal-title":"Clin Neurophysiol"},{"issue":"10","key":"1066_CR16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13(10):1006\u201310. https:\/\/doi.org\/10.1016\/j.jocn.2005.12.041.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"1066_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1066_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40120-025-00850-7","volume":"15","author":"N Numajiri","year":"2026","unstructured":"Numajiri N, Yamamoto T, Waratani M, Takahashi MP. Clinical impact of high-dose corticosteroids on healthcare resource utilization and steroid-related complications in patients with myasthenia gravis in Japan. Neurol Ther. 2026;15(1):127\u201341. https:\/\/doi.org\/10.1007\/s40120-025-00850-7.","journal-title":"Neurol Ther"},{"issue":"6","key":"1066_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/wnl.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383. https:\/\/doi.org\/10.1212\/wnl.50.6.1778.","journal-title":"Neurology"},{"issue":"6","key":"1066_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1602489.","journal-title":"N Engl J Med"},{"issue":"3","key":"1066_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","volume":"18","author":"GI Wolfe","year":"2019","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18(3):259\u201368. https:\/\/doi.org\/10.1016\/S1474-4422(18)30392-2.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1066_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41(6):789\u201396.","journal-title":"Ann Neurol"},{"issue":"3","key":"1066_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173\u201384. https:\/\/doi.org\/10.1385\/CRIAI:29:3:173.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1066_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328. https:\/\/doi.org\/10.1111\/nyas.13522.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1066_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","volume":"39","author":"K Sahashi","year":"1980","unstructured":"Sahashi K, Engel AG, Lambert EH, Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol. 1980;39(2):160\u201372. https:\/\/doi.org\/10.1097\/00005072-198003000-00005.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1066_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14\u201324. https:\/\/doi.org\/10.1002\/mus.26447.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1066_CR27","doi-asserted-by":"publisher","first-page":"e70158","DOI":"10.1111\/ene.70158","volume":"32","author":"TH Vu","year":"2025","unstructured":"Vu TH, Mantegazza R, Annane D, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase\u00a03 CHAMPION MG open-label extension. Eur J Neurol. 2025;32(4):e70158. https:\/\/doi.org\/10.1111\/ene.70158.","journal-title":"Eur J Neurol"},{"key":"1066_CR28","doi-asserted-by":"publisher","first-page":"175628642412431","DOI":"10.1177\/17562864241243186","volume":"17","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Bresch S, Farmakidis C, et al. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord. 2024;17:17562864241243186. https:\/\/doi.org\/10.1177\/17562864241243186.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"1066_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaneurol.2026.2333","volume":"83","author":"KG Gwathmey","year":"2026","unstructured":"Gwathmey KG, Sacc\u00e0 F, Howard JF Jr, et al. Efficacy and safety of gefurulimab in generalized myasthenia gravis: the PREVAIL phase\u00a03 randomized clinical trial. JAMA Neurol. 2026;83(9):841\u201350. \u00a0https:\/\/doi.org\/10.1001\/jamaneurol.2026.2333.","journal-title":"JAMA Neurol"},{"issue":"10540","key":"1066_CR30","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(26)00690-2","volume":"407","author":"T Vu","year":"2026","unstructured":"Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase\u00a03 trial. Lancet. 2026;407(10540):1712\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(26)00690-2.","journal-title":"Lancet"},{"issue":"4","key":"1066_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1083\/jcb.200809122","volume":"185","author":"S Tzaban","year":"2009","unstructured":"Tzaban S, Massol RH, Yen E, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185(4):673\u201384. https:\/\/doi.org\/10.1083\/jcb.200809122.","journal-title":"J Cell Biol"},{"key":"1066_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118074","volume":"430","author":"GI Wolfe","year":"2021","unstructured":"Wolfe GI, Ward ES, de Haard H, et al. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci. 2021;430:118074. https:\/\/doi.org\/10.1016\/j.jns.2021.118074.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1066_CR33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","volume":"14","author":"M Yoshikawa","year":"2025","unstructured":"Yoshikawa M, Inoue Y, Tanaka K, et al. Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation. Neurol Ther. 2025;14(3):977\u201388. https:\/\/doi.org\/10.1007\/s40120-025-00748-4.","journal-title":"Neurol Ther"},{"issue":"6","key":"1066_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2169\/internalmedicine.3726-24","volume":"64","author":"K Tanaka","year":"2025","unstructured":"Tanaka K, Yoshikawa M, Inoue Y, et al. Efgartigimod successfully ameliorated acute exacerbation of myasthenia gravis with anti-muscle-specific kinase antibodies. Intern Med. 2025;64(6):925\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.3726-24.","journal-title":"Intern Med"},{"issue":"2","key":"1066_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase\u00a03, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(24)00498-8.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1066_CR36","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"key":"1066_CR37","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Bril V, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase\u00a03 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2024;14:1284444. https:\/\/doi.org\/10.3389\/fneur.2023.1284444.","journal-title":"Front Neurol"},{"key":"1066_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123264","volume":"466","author":"S Dewilde","year":"2024","unstructured":"Dewilde S, Griffiths A, Qi CZ, et al. Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of efgartigimod in generalized myasthenia gravis. J Neurol Sci. 2024;466:123264. https:\/\/doi.org\/10.1016\/j.jns.2024.123264.","journal-title":"J Neurol Sci"},{"issue":"5","key":"1066_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Vu T, Li G, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase\u00a03 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics. 2024;21(5):e00378. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00378.","journal-title":"Neurotherapeutics"},{"issue":"414","key":"1066_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase\u00a01 study. Sci Transl Med. 2017;9(414):eaan1208. https:\/\/doi.org\/10.1126\/scitranslmed.aan1208.","journal-title":"Sci Transl Med"},{"key":"1066_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/17562864261458532","volume":"19","author":"V Bril","year":"2026","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase\u00a0III MycarinG study and two open-label extensions. Ther Adv Neurol Disord. 2026;19:17562864261458532. https:\/\/doi.org\/10.1177\/17562864261458532.","journal-title":"Ther Adv Neurol Disord"},{"key":"1066_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241273036","volume":"17","author":"AA Habib","year":"2024","unstructured":"Habib AA, Sacconi S, Antonini G, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase\u00a0III MycarinG study. Ther Adv Neurol Disord. 2024;17:17562864241273036. https:\/\/doi.org\/10.1177\/17562864241273036.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"1066_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191","volume":"17","author":"NP Seth","year":"2025","unstructured":"Seth NP, Xu R, DuPrie M, et al. Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties. MAbs. 2025;17(1):2461191. https:\/\/doi.org\/10.1080\/19420862.2025.2461191.","journal-title":"MAbs"},{"issue":"2","key":"1066_CR44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase\u00a02 Vivacity-MG study. Neurology. 2024;102(2):e207937. https:\/\/doi.org\/10.1212\/WNL.0000000000207937.","journal-title":"Neurology"},{"issue":"2","key":"1066_CR45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC. B\u00a0cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172\u201384. https:\/\/doi.org\/10.1002\/mus.25973.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1066_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113\u201324. https:\/\/doi.org\/10.1038\/s41582-018-0110-z.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1066_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000004341.","journal-title":"Neurology"},{"issue":"2","key":"1066_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20(2):84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1066_CR49","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262(5):1115\u20139. https:\/\/doi.org\/10.1007\/s00415-014-7532-3.","journal-title":"J Neurol"},{"issue":"4","key":"1066_CR50","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, et al. Phase\u00a02 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98(4):e376\u201389. https:\/\/doi.org\/10.1212\/WNL.0000000000013121.","journal-title":"Neurology"},{"issue":"11","key":"1066_CR51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105\u201312. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1066_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185\u201396. https:\/\/doi.org\/10.1002\/mus.25597.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1066_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/pn-2025-004655","volume":"25","author":"S Jacob","year":"2025","unstructured":"Jacob S, Farrugia ME, Hewamadduma C, et al. Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). Pract Neurol. 2025;25(5):422\u201337. https:\/\/doi.org\/10.1136\/pn-2025-004655.","journal-title":"Pract Neurol"},{"issue":"8","key":"1066_CR54","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","volume":"32","author":"M Caballero-\u00c1vila","year":"2022","unstructured":"Caballero-\u00c1vila M, \u00c1lvarez-Velasco R, Moga E, et al. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscul Disord. 2022;32(8):664\u201371. https:\/\/doi.org\/10.1016\/j.nmd.2022.06.006.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"1066_CR55","doi-asserted-by":"publisher","first-page":"175628641876169","DOI":"10.1177\/1756286418761697","volume":"21","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, St\u00fcve O. B\u00a0cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;21(11):1756286418761697. https:\/\/doi.org\/10.1177\/1756286418761697.","journal-title":"Ther Adv Neurol Disord"},{"issue":"23","key":"1066_CR56","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, et al. A phase\u00a03 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2501561.","journal-title":"N Engl J Med"},{"issue":"5","key":"1066_CR57","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","volume":"24","author":"JE Kenison","year":"2024","unstructured":"Kenison JE, Stevens NA, Quintana FJ. Therapeutic induction of antigen-specific immune tolerance. Nat Rev Immunol. 2024;24(5):338\u201357. https:\/\/doi.org\/10.1038\/s41577-023-00970-x.","journal-title":"Nat Rev Immunol"},{"key":"1066_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/mus.70255","author":"S El-Wahsh","year":"2026","unstructured":"El-Wahsh S, Chan F, Reddel S. Cure in myasthenia gravis: an unmet need. Muscle Nerve. 2026. https:\/\/doi.org\/10.1002\/mus.70255.","journal-title":"Muscle Nerve"},{"issue":"11","key":"1066_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T\u00a0cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24(11):830\u201345. https:\/\/doi.org\/10.1038\/s41577-024-01035-3.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1066_CR60","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.720.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1066_CR61","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al. Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"issue":"8","key":"1066_CR62","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"key":"1066_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103621","volume":"90","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu D, Zhang Z, et al. Anti-BCMA\/CD19 CAR T\u00a0cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase\u00a01 trial. EClinicalMedicine. 2025;90:103621. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103621.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"1066_CR64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, et al. Advancements and challenges in CAR T\u00a0cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531\u201344. https:\/\/doi.org\/10.1038\/s41584-024-01139-z.","journal-title":"Nat Rev Rheumatol"},{"issue":"6295","key":"1066_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T\u00a0cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179\u201384. https:\/\/doi.org\/10.1126\/science.aaf6756.","journal-title":"Science"},{"issue":"3","key":"1066_CR66","doi-asserted-by":"publisher","first-page":"114924","DOI":"10.1016\/j.isci.2026.114924","volume":"29","author":"W Li","year":"2026","unstructured":"Li W, Yang Q, Lai S, et al. A combinatorial CAAR-T\u00a0cell strategy to eliminate factor VIII inhibitors in preclinical models of hemophilia A. iScience. 2026;29(3):114924. https:\/\/doi.org\/10.1016\/j.isci.2026.114924.","journal-title":"iScience"},{"issue":"9","key":"1066_CR67","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S, et al. Precision targeting of autoantigen-specific B\u00a0cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T\u00a0cells. Nat Biotechnol. 2023;41(9):1229\u201338. https:\/\/doi.org\/10.1038\/s41587-022-01637-z. (Erratum in: Nat Biotechnol. 2024 Dec;42(12):1923. 10.1038\/s41587-024-02502-x).","journal-title":"Nat Biotechnol"},{"issue":"9","key":"1066_CR68","doi-asserted-by":"publisher","first-page":"eadt0795","DOI":"10.1126\/sciadv.adt0795","volume":"11","author":"S Oh","year":"2025","unstructured":"Oh S, Khani-Habibabadi F, O\u2019Connor KC, Payne AS. Composition and function of AChR chimeric autoantibody receptor T\u00a0cells for antigen-specific B\u00a0cell depletion in myasthenia gravis. Sci Adv. 2025;11(9):eadt0795. https:\/\/doi.org\/10.1126\/sciadv.adt0795.","journal-title":"Sci Adv"},{"issue":"6","key":"1066_CR69","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/ene.15266","volume":"29","author":"F Scheibe","year":"2022","unstructured":"Scheibe F, Ostendorf L, Pr\u00fcss H, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847\u201354. https:\/\/doi.org\/10.1111\/ene.15266.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1066_CR70","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","volume":"16","author":"DS Tian","year":"2024","unstructured":"Tian DS, Qin C, Dong MH, et al. B\u00a0cell lineage reconstitution underlies CAR-T\u00a0cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol Med. 2024;16(4):966\u201387. https:\/\/doi.org\/10.1038\/s44321-024-00043-z.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"1066_CR71","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","volume":"32","author":"T Vu","year":"2026","unstructured":"Vu T, Durmus H, Rivner M, et al. BCMA-directed mRNA CAR T\u00a0cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase\u00a02b trial. Nat Med. 2026;32(3):1131\u201341. https:\/\/doi.org\/10.1038\/s41591-025-04171-y.","journal-title":"Nat Med"},{"issue":"3","key":"1066_CR72","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T\u00a0cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151\u201364. https:\/\/doi.org\/10.4049\/jimmunol.155.3.1151.","journal-title":"J Immunol"},{"issue":"3","key":"1066_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","volume":"145","author":"M Thiruppathi","year":"2012","unstructured":"Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T\u00a0cells in patients with myasthenia gravis. Clin Immunol. 2012;145(3):209\u201323. https:\/\/doi.org\/10.1016\/j.clim.2012.09.012.","journal-title":"Clin Immunol"},{"issue":"315","key":"1066_CR74","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, Buckner JH, Fitch M, et al. Type\u00a01 diabetes immunotherapy using polyclonal regulatory T\u00a0cells. Sci Transl Med. 2015;7(315):315ra189. https:\/\/doi.org\/10.1126\/scitranslmed.aad4134.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1066_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56739-2","volume":"14","author":"TT Yang","year":"2024","unstructured":"Yang TT, Liu PJ, Sun QY, et al. CD4+CD25+ regulatory T\u00a0cells ex vivo generated from autologous na\u00efve CD4+ T\u00a0cells suppress EAE progression. Sci Rep. 2024;14(1):6262. https:\/\/doi.org\/10.1038\/s41598-024-56739-2.","journal-title":"Sci Rep"},{"issue":"2","key":"1066_CR76","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41584-024-01201-w","volume":"21","author":"JH Buckner","year":"2025","unstructured":"Buckner JH. Antigen-specific immunotherapies for autoimmune disease. Nat Rev Rheumatol. 2025;21(2):88\u201397. https:\/\/doi.org\/10.1038\/s41584-024-01201-w.","journal-title":"Nat Rev Rheumatol"},{"issue":"6525","key":"1066_CR77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke C, Kolb L, Diken E, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145\u201353. https:\/\/doi.org\/10.1126\/science.aay3638.","journal-title":"Science"},{"issue":"6","key":"1066_CR78","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.4049\/jimmunol.159.6.3016","volume":"159","author":"B Wu","year":"1997","unstructured":"Wu B, Deng C, Goluszko E, Christadoss P. Tolerance to a dominant T\u00a0cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J Immunol. 1997;159(6):3016\u201323.","journal-title":"J Immunol"},{"issue":"16","key":"1066_CR79","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000005323.","journal-title":"Neurology"},{"issue":"8","key":"1066_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X, et al. A multicenter, randomized, open-label, phase\u00a02 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024;31(8):e16322. https:\/\/doi.org\/10.1111\/ene.16322.","journal-title":"Eur J Neurol"},{"key":"1066_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578447","volume":"396","author":"YF Huang","year":"2024","unstructured":"Huang YF, Briggs CM, Gokhale S, Punga AR. Elevated C1s\/C1-INH in serum and plasma of myasthenia gravis patients. J Neuroimmunol. 2024;396:578447. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578447.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1066_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445.","journal-title":"BMJ Open"},{"issue":"4","key":"1066_CR83","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40120-024-00617-6","volume":"13","author":"N Kawaguchi","year":"2024","unstructured":"Kawaguchi N, Tsuda K, Tanaka N, Kerstens R, Harada D. Myasthenia gravis disease burden and its impact on satisfaction with life: a qualitative survey of patients\u2019 perspectives in Japan. Neurol Ther. 2024;13(4):1099\u2013113. https:\/\/doi.org\/10.1007\/s40120-024-00617-6.","journal-title":"Neurol Ther"},{"issue":"9","key":"1066_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70081","volume":"7","author":"M Yung","year":"2024","unstructured":"Yung M, Narayanaswami P, Pesa J, et al. Patient and care partner perspectives and preferences related to myasthenia gravis treatment: a qualitative study. Health Sci Rep. 2024;7(9):e70081. https:\/\/doi.org\/10.1002\/hsr2.70081.","journal-title":"Health Sci Rep"},{"issue":"6","key":"1066_CR85","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/mus.70202","volume":"73","author":"J Lin","year":"2026","unstructured":"Lin J, Qi G, Luo S, et al. Experience using efgartigimod to treat juvenile myasthenia gravis in China: a multicenter retrospective study. Muscle Nerve. 2026;73(6):1025\u201331. https:\/\/doi.org\/10.1002\/mus.70202.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1066_CR86","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1474-4422(25)00479-X","volume":"25","author":"DL Rotstein","year":"2026","unstructured":"Rotstein DL, Alroughani R, Arrambide G, Carnero Contentti E, Chomba M, Fujihara K, et al. Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD. Lancet Neurol. 2026;25(3):308\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(25)00479-X.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1066_CR87","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000218351","volume":"107","author":"NP McLaren","year":"2026","unstructured":"McLaren NP, Rosati M, Zhong W, et al. Comparison of the efficacy and safety of myasthenia gravis treatments: a Bayesian network meta-analysis. Neurology. 2026;107(3):e218351. https:\/\/doi.org\/10.1212\/WNL.0000000000218351.","journal-title":"Neurology"},{"key":"1066_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577424","volume":"349","author":"A Uzawa","year":"2020","unstructured":"Uzawa A, Ozawa Y, Yasuda M, Kuwabara S. Severe worsening of myasthenic symptoms after the eculizumab discontinuation. J Neuroimmunol. 2020;349:577424. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577424.","journal-title":"J Neuroimmunol"},{"key":"1066_CR89","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A, et al. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol. 2024;11:1338\u201346. https:\/\/doi.org\/10.1002\/acn3.52051.","journal-title":"Ann Clin Transl Neurol"},{"key":"1066_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13127-8","volume":"272","author":"E Rossini","year":"2025","unstructured":"Rossini E, Di Stefano V, Iorio R, et al. Ravulizumab for generalized myasthenia gravis: a multicenter real-life experience. J Neurol. 2025;272:396. https:\/\/doi.org\/10.1007\/s00415-025-13127-8.","journal-title":"J Neurol"},{"key":"1066_CR91","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40120-025-00873-0","volume":"15","author":"F Sacc\u00e0","year":"2026","unstructured":"Sacc\u00e0 F, Lee J, Yee KS, Silvestri NJ, Sabatella G. Oral corticosteroid and nonsteroidal immunosuppressant therapy use in patients with myasthenia gravis receiving ravulizumab, eculizumab, or efgartigimod in the USA. Neurol Ther. 2026;15:383\u201399. https:\/\/doi.org\/10.1007\/s40120-025-00873-0.","journal-title":"Neurol Ther"},{"key":"1066_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.125671","volume":"479","author":"V Di Stefano","year":"2025","unstructured":"Di Stefano V, Rini N, Antozzi C, et al. Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. J Neurol Sci. 2025;479:125671. https:\/\/doi.org\/10.1016\/j.jns.2025.125671.","journal-title":"J Neurol Sci"},{"key":"1066_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/22143602261437792","author":"G Tammam","year":"2026","unstructured":"Tammam G, Slioui A, Friedman D, et al. Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: a retrospective cohort study in France. J Neuromuscul Dis. 2026. https:\/\/doi.org\/10.1177\/22143602261437792.","journal-title":"J Neuromuscul Dis"},{"key":"1066_CR94","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40120-026-00939-7","volume":"15","author":"M Kumar","year":"2026","unstructured":"Kumar M, Harrold A, Park M, et al. Treatment characteristics and healthcare resource utilization among patients with myasthenia gravis initiating rozanolixizumab: a US claims database analysis. Neurol Ther. 2026;15:1573\u201391. https:\/\/doi.org\/10.1007\/s40120-026-00939-7.","journal-title":"Neurol Ther"},{"key":"1066_CR95","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11:2212\u201321. https:\/\/doi.org\/10.1002\/acn3.52142.","journal-title":"Ann Clin Transl Neurol"},{"key":"1066_CR96","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mus.28042","volume":"69","author":"A Mehrabyan","year":"2024","unstructured":"Mehrabyan A, Traub RE. Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment. Muscle Nerve. 2024;69:467\u201371. https:\/\/doi.org\/10.1002\/mus.28042.","journal-title":"Muscle Nerve"},{"key":"1066_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418503","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Huan X, et al. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol. 2024;15:1418503. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503.","journal-title":"Front Immunol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01066-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:01:34Z","timestamp":1792814494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01066-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":97,"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01066-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"9 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Haruki Koike is a member of the Editorial Board of\n                      Neurology and Therapy\n                      . Haruki Koike was not involved in the selection of peer reviewers for the manuscript or any subsequent editorial decisions. Masaaki Yoshikawa has nothing to disclose. Toshihiro Ide has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}